The safe and appropriate use of all Bayer medicines is our highest priority. Prescribe Xarelto with care.
This section contains practical guidance and tools to help you identify patients at increased risk of haemorrhagic events, and manage them appropriately.
Bleeding is a safety concern with all anticoagulants
All licenced anticoagulants deliver a positive benefit risk profile. However, all anticoagulants can increase the risk of bleeding.1
Some patients are at greater risk of bleeding
For which patients should Xarelto be prescribed with care, or not at all?
Please refer to the Summary of Product Characteristics for full safety information and precautions for use.
Xarelto is not recommended in patients with an increased bleeding risk such as:2
- congenital or acquired bleeding disorders
- vascular retinopathy
- uncontrolled severe arterial hypertension
- bronchiectasis or history of pulmonary bleeding
- other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)
The importance of patient education and compliance
A major component of responsible use of anticoagulant therapy rests with the patient. To benefit from Xarelto therapy, patients must take their treatment exactly as prescribed.
It is imperative that your patients understand as best as they can the importance of continued anticoagulation.
Patients also need to be able to recognise the signs and symptoms of bleeding and know when they should seek medical attention.
By following this careful path to safe and appropriate Xarelto prescribing, you will help to ensure your patients obtain the greatest therapeutic benefit from treatment, without exposing them to unnecessary risk.